GlassScriptPhysician profile
Erik Randall Ewing
NPI 1316326960
$7,925.44
in general payments reported to CMS, 2019-2025
39 companies · $1,173 in 2025
The $1,173 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $885 · 2020: $968 · 2021: $1,275 · 2022: $972 · 2023: $1,236 · 2024: $1,415 · 2025: $1,173.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,825.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,825.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,530.16 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $939.64 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $761.97 | 2020-2025 | |
| Amgen INC. | $523.72 | 2019-2025 | Otezla, Repatha, Evenity |
| Pfizer INC. | $455.33 | 2019-2025 | |
| Lilly USA, LLC | $341.93 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $329.96 | 2021-2025 | |
| Astellas Pharma US INC | $328.26 | 2019-2023 | Veozah |
| Janssen Pharmaceuticals, INC | $321.08 | 2019-2021 | |
| Amarin Pharma, INC. | $271.81 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $237.15 | 2019-2021 | |
| Glaxosmithkline, LLC. | $236.89 | 2020-2025 | Shingrix, Arexvy, Boostrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $185.95 | 2019-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $154.47 | 2020-2022 | |
| Centinel Spine, LLC | $119.03 | 2019 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erik Ewing listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.